Premier patient traité dans l’essai de phase 3 pour un traitement du cancer du poumon ciblant le biomarqueur TROP2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback